Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw(Dana-Farber Cancer Institute), Pasi A. Jänne(Harvard University), Denis Moro‐Sibilot(Centre Hospitalier Universitaire de Grenoble), Kenneth J. O’Byrne(Translational Research Institute), Myung‐Ju Ahn(Sungkyunkwan University), Vera Hirsh(Taipei Veterans General Hospital), Shrividya Iyer(Pfizer (United States)), Benjamin Solomon(Peter MacCallum Cancer Centre), Vanessa Tassell(Pfizer (United States)), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Keith D. Wilner(Pfizer (United States)), Tommaso De Pas(Mylan (Switzerland)), Tony Mok(Chinese University of Hong Kong), Takashi Seto(National Hospital Organization Kyushu Cancer Center), D. Ross Camidge(University of Colorado Denver), Anna Polli(Pfizer (Italy)), Fiona Blackhall(University of Manchester), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Michael Thomas, Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Dong‐Wan Kim(Seoul National University Hospital), Benjamin Besse(Institut Gustave Roussy)
Cited by 3,405
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k